OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
May 11, 2021
A panel of pharma digital leaders discusses pathways for technology and data scale-up—and the skills, mindset, and C-suite influence needed to drive true digital transformation.
April 14, 2021
In this roundtable discussion, Steve Gens, Remco Munnik and James Kelleher explore the potential and the practicalities of building future processes on a single, joined-up content platform.
February 11, 2021
Panelists in a recent roundtable share ideas on transforming company culture, fostering greater patient diversity, and acting on pharma’s fast-evolving social mandate.
November 30, 2020
Recent roundtable brought together by Pharm Exec and Parexel features insights from leaders in the pharma industry on the current state and future of RWE.
November 16, 2020
Chief financial officers gather virtually to share the stories of directing their company IPOs over the finish line amid the COVID-19 pandemic.
October 14, 2020
A recent roundtable moderated by Rob Jekielek of The Harris Poll gathered five biopharma CEOs to discuss the industry’s shifting reputational landscape in the public eye.
July 01, 2020
A recent roundtable moderated by Dr. Scott Gottlieb gathered biopharma CEOs to share thoughts and strategies on navigating their companies through the COVID-19 outbreak.
July 15, 2019
Pharm Exec sits down with a pair of big pharma compliance leaders to discuss the strategic move to principles-based policies and the impact of other emerging forces influencing industry compliance practice.
January 30, 2019
Financial leaders from clinical-stage biopharma gather to discuss the critical role of finance and accounting (F&A) in supporting and sustaining the science at the forefront of engagement with investors.
July 10, 2018
Pharm Exec convenes an expert panel at CBI’s Pharmaceutical Compliance Congress to discuss new ways to navigate the many complexities when it comes to the crucial task of assessing business and risk in the life sciences.